Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease [Coronary Heart Disease]

Conclusions Although high Lp-PLA2 activity was associated with increased risk of cardiovascular events, pharmacological lowering of Lp-PLA2 activity by 65% did not significantly reduce cardiovascular events in patients with stable coronary heart disease, regardless of the baseline level or the magnitude of change of Lp-PLA2 activity. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT00799903.

http://jaha.ahajournals.org/cgi/content/short/5/6/e003407?rss=1

Source: JAHA:Journal of the American Heart Association - June 20, 2016 Category: Cardiology Authors: Wallentin, L., Held, C., Armstrong, P. W., Cannon, C. P., Davies, R. Y., Granger, C. B., Hagström, E., Harrington, R. A., Hochman, J. S., Koenig, W., Krug-Gourley, S., Mohler, E. R., Siegbahn, A., Tarka, E., Steg, P. G., Stewart, R. A. H., Weiss, Tags: Biomarkers, Risk Factors, Pharmacology, Treatment, Coronary Artery Disease Coronary Heart Disease Source Type: research